secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001213900-25-060352
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Therapeutics appoints Laura Sandler as COO, effective July 1, 2025
------------------------------------------------------------------------

- Base salary of $460,000 per year; eligible for annual bonus targeted at 40% of base.
- Granted option to purchase 25,000 shares of common stock; vests 25% on first anniversary, then monthly over 36 months.
- Severance: 12 months base salary if terminated without cause or for good reason outside change-in-control period.
- Within change-in-control period: severance of 1x base salary plus target bonus, plus full equity acceleration.
- Sandler previously served as SVP of Operations at Oruka since March 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390025060352/0001213900-25-060352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390025060352/ea0247670-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-060352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer